Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. (NYSE: DVA) is a comprehensive kidney care provider whose news flow reflects its clinical, operational and financial activities in the kidney dialysis centers industry. Company press releases and updates highlight its focus on transforming care delivery for patients with kidney disease, its large global network of outpatient dialysis centers and its role in integrated kidney care and value-based care models.
News about DaVita often covers quarterly financial and operating results, where the company reports consolidated revenues, operating income, cash flow and key U.S. dialysis metrics such as treatment volumes, revenue per treatment and patient care costs per treatment. These releases may also discuss share repurchases, debt transactions, credit facility amendments and guidance ranges for adjusted operating income, adjusted diluted net income per share and free cash flow.
Investors and observers can also find updates on clinical research and innovation. DaVita publishes information about studies presented at events like the American Society of Nephrology’s Kidney Week, including research on GLP-1 receptor agonist use in end-stage kidney disease, home dialysis outcomes, transplant access and end-of-life care. Additional news may describe initiatives such as the MODEL and MEMOIRS evaluations of medium cut-off dialyzers and efforts to better understand middle-molecule clearance.
Other DaVita news items include leadership appointments, participation in investor conferences and statements on government programs such as the Kidney Care Choices (KCC) Model. These communications provide insight into the company’s strategy, governance, integrated kidney care footprint and engagement with value-based care initiatives. For ongoing context on DVA, readers can use this news feed to follow developments in DaVita’s kidney care operations, research programs and capital allocation decisions over time.
NephroSant has successfully closed a $16 million Series A funding round, led by DaVita Venture Group with participation from DigitalDx Ventures and others. This funding will support the launch of Qsant™, a non-invasive urine test for detecting kidney transplant rejection. Current rejection rates stand at 40%. Qsant™ simplifies the testing process by using a single urine sample, enhancing patient convenience and safety, especially amid the COVID-19 pandemic. The investment highlights the commitment to improve kidney health and patient outcomes.
DaVita Inc. (NYSE: DVA) will participate in the 2021 Barclays Global Healthcare Conference, with CFO Joel Ackerman addressing questions in a virtual fireside chat on March 10, 2021, at 4:10 p.m. Eastern Time. A live audio webcast will be accessible via DaVita's investor website, with a replay available for 90 days. DaVita is a leading kidney care provider, serving over 204,200 patients across 2,816 outpatient dialysis centers in the U.S. and operating internationally. The company focuses on improving patient care and reducing hospitalizations.
DaVita Inc. (NYSE: DVA) has announced the upsize of its private offering of senior notes from $750 million to $1 billion. These 4.625% notes are due on June 1, 2030 and will be issued at an offering price of 101.750%. The closing of the offering is expected on February 26, 2021. Proceeds will be used to pay down $550 million in revolving credit, cover offering expenses, and support general corporate purposes. The offering is targeted at qualified institutional buyers under Regulation S.
DaVita Inc. (NYSE: DVA) has initiated a private offering of $750 million in additional 4.625% senior notes, maturing on June 1, 2030. These notes will be issued under an existing indenture and will share the same terms as previously issued notes of $1.75 billion. Proceeds will be used to reduce borrowings, cover offering expenses, and for general corporate purposes, including potential stock repurchases. This issuance is targeting qualified institutional buyers and is subject to regulatory compliance.
DaVita reported financial results for Q4 and full-year 2020, with diluted EPS from continuing operations at $6.39, a 38.9% increase year-over-year. Q4 diluted EPS was $1.67, impacted by COVID-19 with a $60 million operating income loss. Total revenues were $2.905 billion for Q4 and $11.551 billion for the year. Operating cash flow was $485 million in Q4, and free cash flow was $210 million. The company served approximately 240,400 patients across 3,137 centers, opening 14 new centers in Q4.
DaVita Inc. (NYSE: DVA) will hold its quarterly conference call on February 11, 2021, at 5:00 p.m. Eastern Time, to discuss fourth quarter results. The results will be released after market close on the same day. This call will be webcast, accessible through the DaVita IR web page. The dial-in number for participants is 877-918-6630, with an international option at 517-308-9042. A replay will be available on DaVita's website after the call. DaVita is a leading provider of kidney care services in the U.S., committed to improving patient care.
Summary not available.
DaVita announced that its annual cycling event, Tour DaVita, raised nearly $1 million for Bridge of Life, a nonprofit focused on global health care. This year's event was adapted to a virtual format due to COVID-19, attracting almost 3,600 participants who logged over 45,000 miles in various activities. Bridge of Life will utilize these funds to enhance health care services, especially to combat COVID-19 in 13 countries. DaVita operates over 2,800 outpatient dialysis centers in the U.S. as of September 2020, emphasizing its commitment to innovative kidney care.
DaVita Kidney Care has expressed gratitude following the defeat of Proposition 23 in California, which could have threatened access to dialysis for over 80,000 patients. The company criticized the SEIU-UHW labor union for its opposition to the dialysis community and reaffirmed its commitment to prioritizing patient health and safety. DaVita is a leading provider of kidney care services in the U.S., serving 205,300 patients at 2,809 centers nationwide as of September 30, 2020, and has been a pioneer in clinical quality and innovation in kidney care.
DaVita Inc. (NYSE: DVA) reported solid financial results for Q3 2020, with consolidated revenues of $2.924 billion and operating income of $438 million, achieving a 15.0% operating margin. Diluted earnings per share from continuing operations rose to $1.28, up from $0.99 in Q3 2019. The company repurchased over 8 million shares at an average cost of $88.13 and maintained strong cash flows, generating $483 million in operating cash flow. However, advocacy costs surged to $66 million due to efforts against union initiatives, impacting general and administrative expenses.